Genetic predictor for il18 driven disease
WO2026136763A1PCT designated stage Publication Date: 2026-06-25BRISTOL MYERS SQUIBB CO
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- BRISTOL MYERS SQUIBB CO
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Existing treatments for immune-mediated diseases, such as inflammatory bowel disease, do not effectively target IL-18 driven or inflammasome-mediated diseases, as not all patients respond equally to standard therapies targeting the IL-18 signaling pathway.
Method used
Generating a polygenic score (PGS) based on the presence of effect alleles at specific SNPs to identify subjects at risk for IL-18 driven or inflammasome-mediated diseases, and administering IL-18 or inflammasome pathway inhibitors based on this score.
Benefits of technology
The PGS effectively identifies subjects who may benefit from IL-18 or inflammasome pathway inhibitors, improving treatment outcomes for immune-mediated diseases like inflammatory bowel disease.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060464_25062026_PF_FP_ABST
Abstract
Provided are methods of generating a polygenic score (PGS) to identify or predict interleukin- 18 (IL- 18) driven disease in a subject, along with methods of treating subjects with various diseases and conditions, such as inflammatory bowel disease, determined to have IL- 18 driven disease or inflammasome-mediated disease based on a PGS.
Need to check novelty before this filing date? Find Prior Art